Delving into the Latest Updates on Live-attenuated hepatitis A virus vaccine(Zhejiang Pukang Biologic Technology Co Ltd) with Synapse

Overview

Basic Info

Drug Type

Live attenuated vaccine, Prophylactic vaccine

Synonyms

Hepatitis A (Live) Vaccine,Freeze-dried, 冻干甲型肝炎减毒活疫苗（浙江普康）

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesDigestive System Disorders

Active Indication

Hepatitis A

Inactive Indication-

Originator Organization

Zhejiang Pukang Biotechnology Co. Ltd.

Active Organization

Zhejiang Pukang Biotechnology Co. Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (01 Jan 2000),

Hepatitis A

Regulation-

Login to view timeline

BackgroundLimited data are currently available regarding the cellular immune response to a live attenuated hepatitis A virus (HAV) vaccine, especially in children with obesity. The objective of this retrospective cohort study was to compare the activation of antigen-specific interferon (IFN)-γ+ T cells in obese children and adolescents with healthy individuals before and after immunization with a single dose of live attenuated HAV vaccine.MethodsBlood samples were obtained from the 2021 study by Dumrisilp et al. investigating the immunogenicity of the live attenuated hepatitis A vaccine in children and young adults. Prior to enrollment, all 212 subjects had never received any HAV vaccine and tested negative for anti-HAV antibodies. The participants were vaccinated with a freeze-dried, live attenuated HAV vaccine of the H2 strain. In this study, we analyzed the stored peripheral blood mononuclear cells (PBMCs) obtained from a subgroup of 30 obese subjects and 30 normal-weight healthy controls of the same age and sex. PBMCs were collected before and 8-9 weeks after HAV vaccination for further analysis. These cells were stimulated with a recombinant antigen derived from HAV-VP3, and the immune response was evaluated using the IFN-γ enzyme-linked immunospot (ELISpot) assay.ResultsThe between-group analysis indicated that the T-cell response of obese participants was comparable to that of normal-weight controls both before and after vaccination. The change in IFN-γ production from before to after vaccination in the obese group was not significantly different from that of the control group. Additionally, in the obese group, no correlation was found between IFN-γ production and clinical characteristics such as sex, body mass index, waist circumference, and acanthosis nigricans.ConclusionTesting for cellular immune response provides a comprehensive understanding of the overall immune response to vaccination. This study, the first to explore this significant aspect, suggests that obesity does not affect the short-term cellular immune response to live attenuated HAV vaccination.

26 Oct 2022·Journal of Virology

Optimizing the Live Attenuated Influenza A Vaccine Backbone for High-Risk Patient Groups

Article

Author: Bonifacio, João P. P. L. ; Schmolke, Mirco ; Williams, Nathalia ; Garnier, Laure ; Mazel-Sanchez, Beryl ; Hugues, Stephanie

Live attenuated influenza vaccine (LAIV) is a needle-free, mucosal vaccine approved for healthy 2- to 49-year old individuals. Its replicative nature and higher rate of adverse events excludes at-risk populations.

01 Dec 2021·Journal of Viral HepatitisQ2 · MEDICINE

Long‐term persistence of anti‐HAV antibody conferred by a single dose of live‐attenuated hepatitis A vaccine: Results from 17‐year follow‐up

Q2 · MEDICINE

Article

Author: Zhao, Gan ; Kilgore, Paul E. ; Zhao, Yu‐Liang ; Qiu, Chao ; Zhang, Yan‐Hong ; Wang, Song‐Mei ; Ma, Jing‐Chen ; Zhang, Xin‐Jiang ; Chen, Ying ; Wang, Xuan‐Yi ; Hao, Zhi‐Yong ; Zhang, Zhi‐Yong

In this report, we provide a comprehensive assessment of antibody persistence at 17-yr following receipt of single dose of HA vaccine.

100 Deals associated with Live-attenuated hepatitis A virus vaccine(Zhejiang Pukang Biologic Technology Co Ltd)

Login to view more data